What is Pure Biologics S.A.'s (PUR.WA) StockRank?

MoatMap's StockRank for Pure Biologics S.A. (PUR.WA) is 3/100, with a Strong Sell signal. This is a composite score combining Quality (15), Value (25), and Momentum (25) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Pure Biologics S.A. have an economic moat?

Pure Biologics S.A. (PUR.WA) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Pure Biologics S.A. a buy, hold, or sell?

MoatMap's current signal for Pure Biologics S.A. (PUR.WA) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Pure Biologics S.A. in?

Pure Biologics S.A. (PUR.WA) operates in the Healthcare sector, specifically the Biotechnology industry (Poland).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

PUR.WA

Strong SellSinker

Pure Biologics S.A. · Healthcare · Poland · $8M

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

—

D/E

—

Dividend %

—

COMPANY DESCRIPTION

Pure Biologics S.A. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drugs and therapeutic aptamers, primarily in oncology and immuno-oncology. The company utilizes proprietary technology platforms, such as PureSelect and PureTarg, to identify and select highly specific therapeutic molecules. It operates as a specialized niche player in the European biotechnology sector, relying on strategic partnerships and licensing agreements for late-stage clinical development.

FINANCIAL SUMMARY (PLN)

Year	2022	2023	2024	2025	CAGR	TTM
Revenue	0.7M	0	0	0	—	—
EPS (PLN)	-2.09	-4.76	-2.38	-1.99	—	-1.68
Shares	12.2M	7.8M	8.8M	11.3M	-7.5%	12.2M
Debt	2.9M	12.9M	14.1M	16.0M	77.5%	16.4M
Equity	18.3M	1.9M	-13.1M	-14.1M	-89.7%	—
Op CF	-17.4M	-23.3M	-10.8M	-6.2M	—	-8.6M
Inv CF	15.3M	0.4M	3.6M	0.9M	—	—
Fin CF	-1.9M	24.2M	4.0M	5.0M	—	—

Loading 1Y...

PRICE (1Y)+25.6%

SMA 50SMA 200

$0.7189

SCORE BREAKDOWN

Quality

ROIC (ROA)

-211.7%*2.5

ROE

—N/A

GP/Assets

-0.5%8.3

Op. Margin

0.0%38.1

FCF/Assets

-84.2%3.0

Piotroski

321.9

Int. Cover

-2.6x30.7

D/E Ratio

—N/A

Current Ratio

0.09x0.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-7.5x25.0

P/FCF

—N/A

P/B

-2.2x25.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

—N/A

RS 6M

—N/A

SMA 50/200

—N/A

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$8M

P/E (Forward)

—

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of PUR.WA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
PUR.WA	Pure Biologics S.A.(you)	$8M	3	Strong Sell
MQR.WA	MultiQure S.A.	$10M	3	Strong Sell
URT.WA	Urteste S.A.	$18M	12	Strong Sell
MAB.WA	Mabion S.A.	$34M	10	Strong Sell
NNG.WA	NanoGroup S.A.	$28M	14	Strong Sell
PTG.WA	Poltreg S.A.	$34M	13	Strong Sell
MOC.WA	Molecure S.A.	$40M	14	Strong Sell
SVE.WA	Synthaverse S.A.	$46M	11	Strong Sell
RVU.WA	Ryvu Therapeutics S.A.	$113M	4	Strong Sell
CTX.WA	Captor Therapeutics Spolka Akcyjna	$120M	6	Strong Sell

Peer medians: ROE -17.6% · P/E 17.0x · Gross margin 30.3%

Pure Biologics S.A. (PUR.WA): Stock Score Summary

Pure Biologics S.A. (PUR.WA) has a MoatMap StockRank of 3/100 based on Quality (15/100), Value (25/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$0.72
Market Cap	$8M
Price/Book	-2.19
Operating Margin	0.0%
Free Cash Flow	$-1M

Pure Biologics S.A. operates in the Biotechnology industry, part of the Healthcare sector (Poland).

Frequently Asked Questions

What is Pure Biologics S.A.’s (PUR.WA) StockRank?: MoatMap’s StockRank for Pure Biologics S.A. (PUR.WA) is 3/100, with a Strong Sell signal. It is a composite of Quality (15), Value (25), and Momentum (25) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Pure Biologics S.A. have an economic moat?: Pure Biologics S.A. (PUR.WA) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Pure Biologics S.A. a buy, hold, or sell?: MoatMap’s current signal for Pure Biologics S.A. (PUR.WA) is Strong Sell, based on a StockRank of 3/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Pure Biologics S.A. in?: Pure Biologics S.A. (PUR.WA) operates in the Healthcare sector, specifically the Biotechnology industry (Poland).